Cite
O'Neil CR, Pang JX, Lee SS, et al. Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients. Can J Infect Dis Med Microbiol. 2015;26(6):293-6doi: 10.1155/2015/974871.
O'Neil, C. R., Pang, J. X., Lee, S. S., Swain, M. G., Burak, K. W., Klein, P., Myers, R. P., Kapler, J., Gill, M. J., Labrie, M., & Coffin, C. S. (2015). Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients. The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 26(6), 293-6. https://doi.org/10.1155/2015/974871
O'Neil, Conar R, et al. "Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients." The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale vol. 26,6 (2015): 293-6. doi: https://doi.org/10.1155/2015/974871
O'Neil CR, Pang JX, Lee SS, Swain MG, Burak KW, Klein P, Myers RP, Kapler J, Gill MJ, Labrie M, Coffin CS. Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients. Can J Infect Dis Med Microbiol. 2015 Nov-Dec;26(6):293-6. doi: 10.1155/2015/974871. PMID: 26744584; PMCID: PMC4692296.
Copy
Download .nbib